MAX BioPharma and Technomark Life Sciences announced their collaboration in the development of MAX BioPharma’s oxysterol drug candidate, Oxy210, targeting metabolic dysfunction-associated steatohepatitis (MASH). As a strategic lead investor, Technomark is participating in MAX BioPharma’s $13 million Series A raise to initiate and complete a Phase 1a/1b first-in-human study and is inviting aligned investors from the industry to join this opportunity.

Read the full press release >